Kang-Birken S Lena, Prichard John G
Ventura County Medical Center Immunology Clinic, Ventura, California, USA.
Pharmacotherapy. 2006 Nov;26(11):1646-9. doi: 10.1592/phco.26.11.1646.
A 37-year-old Hispanic man with advanced acquired immunodeficiency syndrome developed extensive pulmonary disease with persistent cough, fever, night sweats, worsening dyspnea, and weight loss. Sputum samples showed scant growth of acid-fast bacilli. He failed to respond to the standard tuberculosis regimen of isoniazid, rifampin, ethambutol, and pyrazinamide. Subsequently, Mycobacterium szulgai was identified, and susceptibility tests showed it to be resistant to all four of those agents. Therapy was changed to clarithromycin, doxycycline, ciprofloxacin, and amikacin. Within 2 weeks, the patient's condition improved significantly, and 6 months after treatment, extensive pulmonary infiltrates had nearly resolved. Fewer than 1% of all human isolates of mycobacteria consist of M. szulgai, which is relatively susceptible to standard antimycobacterial agents. To our knowledge, this is the first reported case of M. szulgai with resistance to all primary antituberculosis drugs.
一名37岁患有晚期获得性免疫缺陷综合征的西班牙裔男子出现广泛肺部疾病,伴有持续咳嗽、发热、盗汗、呼吸困难加重和体重减轻。痰液样本显示抗酸杆菌生长稀少。他对异烟肼、利福平、乙胺丁醇和吡嗪酰胺的标准抗结核治疗方案无反应。随后,鉴定出苏尔加分枝杆菌,药敏试验显示其对所有这四种药物均耐药。治疗改为克拉霉素、多西环素、环丙沙星和阿米卡星。两周内,患者病情显著改善,治疗6个月后,广泛的肺部浸润几乎消退。在所有人类分枝杆菌分离株中,苏尔加分枝杆菌不到1%,它相对易受标准抗分枝杆菌药物的影响。据我们所知,这是首例报告的对所有一线抗结核药物耐药的苏尔加分枝杆菌病例。